Advertisement

Journal of Neuro-Oncology

, Volume 66, Issue 1–2, pp 91–99 | Cite as

Drug-Induced Apoptosis by a Matrix Metalloproteinase Inhibitor, SI-27 on Human Malignant Glioma Cell Lines; in vitro Study

  • Ryuzaburo Kanazawa
  • Daizo Yoshida
  • Hiroshi Takahashi
  • Yuichi Sugisaki
  • Satoru Suzuki
  • Akira Teramoto
Article

Abstract

Matrix metalloproteinase (MMP) plays important roles in cell invasion and tumor angiogenesis. SI-27, an anti-MMP agent, has already been shown to possess both in vitro anti-invasive and anti-angiogenic properties against malignant gliomas in non-cytotoxic dose concentrations. However, to the best of our knowledge, the molecular mechanism mediating the cytotoxic action by this agent and the molecular mechanism in the cytotoxic action against malignant glioma cell have not yet been clarified. Therefore, we assessed the effect in the cytotoxic dose concentrations to investigate whether this cytotoxic action is related to apoptosis in this study. The effect on human glioma cell lines (U87MG, U251MG, and U373MG) was examined by transmission electron microscope, agarose gel electrophoresis with the DNA fragmentation, flow cytometry with FITC-conjugated Annexin V, and detection of caspase activity. Drug-induced apoptosis was observed in the cytotoxic dose. The result indicated that the cytotoxity of SI-27 might be related to the drug-induced apoptosis mediated by caspase.

apoptosis caspase malignant glioma matrix metalloproteinase SI-27 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Yoshida D, Noha M, Watanabe K, Sugisaki Y, Teramoto A: Novel approach to analysis of in vitro tumor angiogenesis with a variable pressure scanning electron microscope: suppression by matrix metalloproteinase inhibitor SI-27. Brain Tumor Pathol 18: 89-100, 2001Google Scholar
  2. 2.
    Yoshida D, Noha M, Watanabe K, Sugisaki Y, Teramoto A: SI-27, a novel inhibitor of matrix metalloproteinases with antiangiogenic activity: detection with a variable-pressure scanning electron microscope. Neurosurgery 50: 578-587, 2002Google Scholar
  3. 3.
    Yoshida D, Watanabe K, Noha M, Takahashi H, Teramoto A: Suppression of matrix metalloproteinase activity by SI-27: detection by a new activity assay with S-2444, a specific chromogenic peptide. J Neuro-Oncol 58: 1-11, 2002Google Scholar
  4. 4.
    Yoshida D, Watanabe K, Noha M, Takahashi H, Teramoto A, Sugisaki Y: Anti-invasive effect of an anti-matrix metalloproteinase agent in a murine brain slice model using the serial monitoring of green fluorescent protein-labeled glioma cells. Neurosurgery 52: 187-197, 2003Google Scholar
  5. 5.
    Esser S, Lampugnani MG, Corada M, Dejana E, Risau W: Vascular endothelial growth factor induces VE-cadherin tyrosin phospholation in endothelial cells. J Cell Sci 111: 1853-1865, 1998Google Scholar
  6. 6.
    Forsyth PA, Wong H, Laing TD, Rewcastle NB, Morris DG, Muzik H, Leco KJ, Johnston RN, Brasher PM, Sutherland G, Edwards DR: Gelatinase-A (MMP-2), gelatinase-B (MMP-9) and membrane type matrix metalloproteinase-1 (MT1-MMP) are involved in different aspects of the pathophysiology of malignant gliomas. Br J Cancer 79: 1828-1835, 1999Google Scholar
  7. 7.
    Kumar R, Yoneda J, Bucana CD, Fidler IJ: Regulation of distinct steps of angiogenesis by different angiogenic molecules. Int J Oncol 12: 749-757, 1998Google Scholar
  8. 8.
    Kvanta A, Sarman S, Fagerholm P, Seregard S, Steen B: Expression of matrix metalloproteinase-2 (MMP-2) and vascular endothelial growth factor (VEGF) in inflammation-associated corneal neovascularization. Exp Eye Res 70: 419-428, 2000Google Scholar
  9. 9.
    Lund-Johansen M, Rucklidge GJ, Milne G, Bjerkvig R: A metalloproteinase, capable of destroying cultured brain tissue isolated from rat glioma cells. Anticancer Res 11: 1001-1006, 1991Google Scholar
  10. 10.
    Moses MA: The regulation of neovascularization of matrix metalloproteinases and their inhibitors. Stem Cells 15: 180-189, 1997Google Scholar
  11. 11.
    Nakano A, Tani E, Miyazaki K, Yamamoto Y, Furuyama J: Matrix metalloproteinases and tissue inhibitors of metalloproteinases in human gliomas. J Neurosurg 81: 298-307, 1995Google Scholar
  12. 12.
    Parliament MB, Allalunis-Turner MJ, Franko AJ, Olive PL, Mandyam R, Santos C, Wolokoff B: Vascular endothelial growth factor expression is independent of hypoxia in human malignant glioma spheroids and tumours. Br J Cancer 82: 635-641, 2000Google Scholar
  13. 13.
    Naito K, Kanbayashi N, Nakajima S, Murai T, Arakawa K, Nishimura S, Okuyama A: Inhibition of growth of human tumor cells in nude mice by a metalloproteinase inhibitor. Int J Cancer 58: 730-735, 1994Google Scholar
  14. 14.
    Watanabe K, Yoshida D, Noha M, Teramoto A: Suppression of matrix metalloproteinase-2 and-9 mediated invasiveness by a novel matrix metalloproteinase inhibitor, BE16627B. J Neuro-Oncol 52: 1-9, 2001Google Scholar
  15. 15.
    Yong VW, Krekoski CA, Forsyth PA, Bell R, Edwards DR: Matrix metalloproteinases and diseases of the CNS. Trends Neurosci 21: 75-80, 1998Google Scholar
  16. 16.
    Kondoh M, Tasaki E, Araragi S, Takiguchi M, Higashimoto M, Watanabe Y, Sato M: Requirement of caspase and p38MARK activation in zinc-induced apoptosis in human leukemia HL-60 cells. Eur J Biochem 269: 6204-6211, 2002Google Scholar
  17. 17.
    Noha M, Yoshida D, Watanabe K, Teramoto A: Suppression of cell invasion on human malignant glioma cell lines by a novel matrix-metalloproteinase inhibitor SI-27: in vitro study. J Neuro-Oncol 48: 217-223, 2000Google Scholar
  18. 18.
    Sandstrom M, Johansson M, Sandstrom J, Bergenheim AT, Henriksson R: Expression of the proteolytic factors, tPA and uPA, PAI-1 and VEGF during malignant glioma progression. Int J Dev Neurosci 17: 473-481, 1999Google Scholar
  19. 19.
    Varlet P, Guillamo JS, Nataf F, Koziak M, Beuvon F, Daumas-Duport C: Vascular endothelial growth factor expression in oligodendrogliomas: a correlative study with Sainte-Anne malignancy grade, growth fraction and patient survival. Neuropathol Appl Neurobiol 26: 379-389, 2000Google Scholar
  20. 20.
    Groves MD, Puduvalli VK, Hess KR, Jaeckle KA, Peterson P, Yung WK, Levin VA: Phase II trial of temozolomide plus the matrix metalloproteinase inhibitor, marimastat, in recurrent and progressive glioblastoma multiforme. J Clin Oncol 20: 1383-1388, 2002Google Scholar
  21. 21.
    Lafuente JV, Adan B, Alkiza K, Garibi JM, Rossi M, Cruz-Sanchez FF: Expression of vascular endothelial growth factor (VEGF) and platelet-derived growth factor receptor-β (PDGFR-β) in human gliomas. J Mol Neurosci 13: 177-185, 1999Google Scholar
  22. 22.
    Quirt I, Bodurth A, Lohmann R, Rusthoven J, Belanger K, Young V, Wainman N, Stewar W, Eisenhauser E: Phase II study of marimastat (BB-2516) in malignant melanoma: a clinical and tumor biopsy study of the National Cancer Institute of Canada Clinical Trials Group. Invest New Drugs 20: 431-437, 2002Google Scholar
  23. 23.
    Watson SA, Morris TM, Collins HM, Bawden LJ, Hawkins K, Bone EA: Inhibition of tumor growth by marimastat in a human xenograft model of gastric cancer: relationship with levels of circulating CEA. Br J Cancer 81: 19-23, 1999Google Scholar
  24. 24.
    Price A, Shi Q, Morris D, Wilcox ME, Brasher PM, Rewcastle NB, Shalinsky D, Zou H, Appelt K, Johnston RN, Yong VW, Edwards D, Forsyth P: Marked inhibition of tumor growth in a malignant glioma tumor model by a novel synthetic matrix metalloproteinase inhibitor AG3340. Clin Cancer Res 5: 845-854, 1999Google Scholar
  25. 25.
    Mitsiades N, Poulaki V, Leone A, Tsokos M: Fas-mediated apoptosis in Ewing's sarcoma cell lines by metalloproteinase inhibitors. J Natl Cancer Inst 91: 1678-1684, 1999Google Scholar
  26. 26.
    Lozonschi L, Sunamura M, Kobari M, Egawa S, Ding L, Matsuno S: Controlling tumor angiogenesis and metastasis of C26 murine colon adenocarcinoma by a new matrix metalloproteinase inhibitor, KB-R7785, in two tumor models. Cancer Res 59: 1252-1258, 1999Google Scholar
  27. 27.
    Katori H, Baba Y, Imagawa Y, Nishimura G, Kagesato Y, Takagi E, Ishii A, Yanoma S, Maekawa R, Yoshioka T, Nagashima Y, Kato Y, Tsukuda M: Reduction of in vivo tumor growth by MMI-166, a selective matrix metalloproteinase inhibitor, through inhibition of tumor angiogenesis in squamous cell carcinoma cell lines of head and neck. Cancer Lett 178: 151-159, 2002Google Scholar
  28. 28.
    Matsushita A, Onda M, Uchida E, Maekawa R, Yoshioka T: Antitumor effect of a new selective matrix metalloproteinase inhibitor, MMI-166, on experimental pancreatic cancer. Int J Cancer 92: 434-440, 2001Google Scholar
  29. 29.
    Gatto C, Rieppi M, Borsotti P, Innocenti S, Ceruti R, Drudis T, Scanziani E, Casazza AM, Taraboletti G, Giavazzi R: BAY 12-9566, a novel inhibitor of matrix metalloproteinases with antiangiogenic activity. Clin Cancer Res 5: 3603-3607, 1999Google Scholar
  30. 30.
    Wylie S, MacDonald IC, Varghese HJ, Schmidt EE, Morris VL, Groom AC, Chambers AF: The matrix metalloproteinase inhibitor batimastat inhibits angiogenesis in liver metastasis of B16F1 melanoma cells. Clin Exp Metastasis 17: 111-117, 1999Google Scholar
  31. 31.
    Lund EL, Spang-Thomsen M, Skovgaard-Poulsen H, Kristjansen PE: Tumor angiogenesis: a new therapeutic target in gliomas. Acta Neurol Scand 97: 52-62, 1998Google Scholar
  32. 32.
    Shalinsky DR, Brekken J, Zou H, McDermott CD, Forsyth P, Edwards D, Margosiak S, Bender S, Truitt G, Wood A, Varki NM, Appelt K: Broad antitumor and antiangiogenic activities of AG3340, a potent and selective MMP inhibitor undergoing advanced oncology clinical trials. Ann Neurochir Suppl(Wien) 68: 105-110, 1997Google Scholar
  33. 33.
    Tonn JC, Kerkau S, Hanke A, Bouterfa H, Mueller JG, Wangner S, Vince GH, Roosen K: Effect of synthetic matrix-metalloproteinase inhibitors on invasive capacity and proliferation of human malignant gliomas in vitro. Int J Cancer 80: 764-772, 1999Google Scholar
  34. 34.
    Nakamura Y, Sato K, Wakimoto N, Kimura F, Okuyama A, Motoyoshi K: A new matrix metalloproteinase inhibitor SI-27 induces apoptosis in several human myeloid leukemia cell lines and enhances sensitivity to TNF alpha-induced apoptosis. Leukemia 15: 1217-1224, 2001Google Scholar

Copyright information

© Kluwer Academic Publishers 2004

Authors and Affiliations

  • Ryuzaburo Kanazawa
    • 1
  • Daizo Yoshida
    • 1
  • Hiroshi Takahashi
    • 1
  • Yuichi Sugisaki
    • 2
  • Satoru Suzuki
    • 3
  • Akira Teramoto
    • 1
  1. 1.Department of NeurosurgeryNippon Medical SchoolTokyoJapan
  2. 2.Central Institute for Electron Microscopic ResearchesNippon Medical SchoolTokyoJapan
  3. 3.Department of Biochemistry and Molecular BiologyNippon Medical SchoolTokyoJapan

Personalised recommendations